Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextromethorphan + bupropion with or without behavioral activation therapy for treatment-resistant depression
ACTRN12625000321448Phase 2Not yet recruiting
- Sponsor
- University of Otago
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dextromethorphan and bupropion in treatment-resistant depression (TRD) and major depressive disorder (MDD) (2 arms), sponsored by University of Otago. Primary endpoint: Depression. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
dextromethorphanbupropion
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12625000321448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000321448.